CytomX Therapeutics, Inc.
NASDAQ:CTMXBiotechnology
-$0.03 today
- Market cap
- $409.85M
- Beta
- 2.09
- P/E (TTM)
- -8.8
- EPS (TTM)
- -$0.33
Volume 4.39M
Average 4.99M
CTMX Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
CytomX Therapeutics, Inc.NASDAQ: CTMX
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $4.71M rose 134.4% year over year, ahead of the +17.3% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 218.2% from the prior quarter. Over 3 fiscal years it compounded at -21.7% a year.
Context
- Stock-based compensation amounted to 8.3% of revenue in FY2025, up 2.7 pp from a year earlier.
- Stock-based compensation increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +134.4% holds above the trailing-twelve-month pace of +17.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 6.3M USD
- Year-over-year change
- -17.8%
- 4-year CAGR
- -16.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.3M | -17.8% |
| FY2024 | 2024-12-31 | 7.67M | -10.4% |
| FY2023 | 2023-12-31 | 8.56M | -34.8% |
| FY2022 | 2022-12-31 | 13.13M | -0.3% |
| FY2021 | 2021-12-31 | 13.17M | — |
Stock-Based Compensation vs competitors
How CTMX compares with its peers on the latest reported figures
- CTMX's LTM Mar 2026 stock-based compensation of $9.12M is the 8th largest of the 10 companies compared; the peer median is $12.63M.
- Its year-over-year change of +17.3% is the 3rd highest of 9, against a peer median of +4.0%.
- Stock-based compensation amounts to 25.6% of revenue for CTMX, versus a peer median of 16.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Jun 2026 | $39.03M | +10.2% | -4.0% | 37.2% | |
| LTM Sep 2026 | $37.94M | +56.7% | +91.1% | 14.3% | |
| LTM Sep 2026 | $36.81M | -0.7% | — | 32869.6% | |
| LTM Mar 2026 | $12.63M | +26.4% | -48.5% | 16.0% | |
| LTM Mar 2026 | $12.55M | -55.6% | -11.3% | 8.0% | |
| LTM Mar 2026 | $10.03M | -58.5% | -18.9% | 10.1% | |
| LTM Mar 2026 | $9.12M | +17.3% | -21.7% | 25.6% | |
| LTM Mar 2026 | $8.17M | -33.3% | -9.2% | 59.0% | |
| LTM Jun 2024 | $7.27M | — | -29.1% | 891.4% | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding CTMX) | $12.63M | +4.0% | -10.2% | 16.0% | |
Competitors are the stored peer set for CTMX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (83.61M) | (99.32M) | (569K) | 31.87M | (17.37M) |
| Depreciation & Amortization | 2.71M | 5.86M | 2.18M | 1.77M | 1.38M |
| Deferred Income Tax | 272K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 13.17M | 13.13M | 8.56M | 7.67M | 6.3M |
| Change in Working Capital | (54.7M) | (30.65M) | (62.51M) | (126.42M) | (68.58M) |
| Accounts Receivables | 8K | (35.2M) | 32.55M | 329K | 1.09M |
| Inventory | 11.64M | 0 | 0 | 0 | 0 |
| Accounts Payables | (139K) | 68K | (1.43M) | (297K) | 221K |
| Other Working Capital | (66.21M) | 4.47M | (93.64M) | (126.45M) | (69.89M) |
| Other Non-Cash Items | 3.13M | 13.33M | (3.69M) | (1.12M) | 2.68M |
| Operating Cash Flow | (119.03M) | (110.79M) | (56.04M) | (86.23M) | (75.59M) |
| Capital Expenditures | (1.61M) | (1.74M) | (840K) | (310K) | (220K) |
| Acquisitions (Net) | (24.1M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (99.9M) | 0 | (424.83M) | (155.49M) | (192.52M) |
| Sales of Investments | 124M | 100M | 275M | 255.5M | 133M |
| Other Investing Activities | 24.1M | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 22.49M | 98.26M | (150.67M) | 99.7M | (59.74M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 107.71M | 648K | 30.23M | 6.91M | 110.45M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.5M | 0 | 0 | 613K | 0 |
| Financing Cash Flow | 110.21M | 648K | 30.23M | 7.52M | 110.45M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 13.67M | (11.88M) | (176.48M) | 20.99M | (24.89M) |
| Free Cash Flow | (120.64M) | (112.53M) | (56.88M) | (86.54M) | (75.81M) |
CytomX Therapeutics, Inc.
NASDAQ:CTMX
Intrinsic Alpha fair value
Locked
Current Price
$1.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.